Dianthus Therapeutics (DNTH) Financials

$18.98 -0.23 (-1.20%)

As of 04:00 PM Eastern

Annual Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-28	-44	-85
Consolidated Net Income / (Loss)	-28	-44	-85
Net Income / (Loss) Continuing Operations	-28	-44	-85
Total Pre-Tax Income	-28	-44	-85
Total Operating Income	-30	-48	-102
Total Gross Profit	6.42	2.83	6.24
Total Revenue	6.42	2.83	6.24
Operating Revenue	6.42	2.83	6.24
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	36	51	108
Selling, General & Admin Expense	6.74	18	25
Research & Development Expense	29	33	83
Total Other Income / (Expense), net	1.23	4.62	17
Interest & Investment Income	1.15	4.76	17
Other Income / (Expense), net	0.08	-0.15	-0.47
Basic Earnings per Share	($32.57)	($8.45)	($2.55)
Weighted Average Basic Shares Outstanding	874.23K	5.15M	33.31M
Diluted Earnings per Share	($32.57)	($8.45)	($2.55)
Weighted Average Diluted Shares Outstanding	874.23K	5.15M	33.31M
Weighted Average Basic & Diluted Shares Outstanding	60.64M	29.35M	32.13M
Cash Dividends to Common per Share	-	$0.00	$0.00

This table shows Dianthus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-7.78	20	-7.09	-11	-15	-11	-14	-18	-25	-28
Consolidated Net Income / (Loss)	-7.78	20	-7.09	-11	-15	-11	-14	-18	-25	-28
Net Income / (Loss) Continuing Operations	-7.78	20	-7.09	-11	-15	-11	-14	-18	-25	-28
Total Pre-Tax Income	-7.78	20	-7.09	-11	-15	-11	-14	-18	-25	-28
Total Operating Income	-8.25	20	-7.68	-12	-16	-13	-18	-22	-30	-32
Total Gross Profit	1.17	5.24	0.48	0.97	0.92	0.46	0.87	1.86	2.17	1.33
Total Revenue	1.17	5.24	0.48	0.97	0.92	0.46	0.87	1.86	2.17	1.33
Operating Revenue	1.17	-	0.48	0.97	0.92	0.46	0.87	1.86	2.17	1.33
Total Operating Expenses	9.43	-15	8.16	13	17	13	19	24	32	33
Selling, General & Admin Expense	2.21	-9.23	2.31	2.49	8.72	4.63	5.64	6.00	6.53	6.83
Research & Development Expense	7.22	-5.99	5.85	10	7.96	8.78	13	18	26	26
Total Other Income / (Expense), net	0.47	-0.94	0.59	0.64	1.00	2.39	4.10	4.60	4.73	3.48
Interest & Investment Income	0.42	-0.97	0.61	0.69	1.03	2.44	4.22	4.71	4.45	3.99
Other Income / (Expense), net	0.05	-	-0.01	-0.05	-0.03	-0.05	-0.13	-0.11	0.28	-0.51
Basic Earnings per Share	($8.90)	($22.99)	($8.10)	($12.73)	($3.78)	$16.16	($0.54)	($0.51)	($0.74)	($0.76)
Weighted Average Basic Shares Outstanding	874.33K	874.23K	874.71K	874.90K	3.91M	5.15M	25.67M	34.23M	34.24M	33.31M
Diluted Earnings per Share	($8.90)	($22.99)	($8.10)	($12.73)	($3.78)	$16.16	($0.54)	($0.51)	($0.74)	($0.76)
Weighted Average Diluted Shares Outstanding	874.33K	874.23K	874.71K	874.90K	3.91M	5.15M	25.67M	34.23M	34.24M	33.31M
Weighted Average Basic & Diluted Shares Outstanding	-	60.64M	60.65M	60.66M	14.82M	29.35M	29.35M	29.35M	29.60M	32.13M

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	7.79	117	-109
Net Cash From Operating Activities	-29	-37	-78
Net Cash From Continuing Operating Activities	-29	-37	-78
Net Income / (Loss) Continuing Operations	-28	-44	-85
Consolidated Net Income / (Loss)	-28	-44	-85
Depreciation Expense	0.03	0.07	0.10
Amortization Expense	-0.49	-1.14	-5.70
Non-Cash Adjustments To Reconcile Net Income	1.59	3.65	13
Changes in Operating Assets and Liabilities, net	-1.72	4.11	-0.54
Net Cash From Investing Activities	-60	20	-287
Net Cash From Continuing Investing Activities	-60	20	-287
Purchase of Property, Plant & Equipment	-0.14	-0.11	-0.11
Purchase of Investments	-62	-57	-414
Sale and/or Maturity of Investments	2.00	78	127
Net Cash From Financing Activities	97	134	256
Net Cash From Continuing Financing Activities	97	134	256
Repayment of Debt	0.00	-0.38	0.00
Issuance of Debt	0.00	0.38	0.00
Issuance of Common Equity	-	0.00	25
Other Financing Activities, net	0.00	134	231
Cash Interest Paid	0.00	0.00	0.00
Cash Income Taxes Paid	0.00	0.00	0.00

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	106	-22	7.85	17	117	-25	197	-16	-280	-11
Net Cash From Operating Activities	16	-8.85	-10	-4.73	-9.99	-12	-15	-15	-21	-27
Net Cash From Continuing Operating Activities	17	-8.85	-10	-4.73	-9.99	-12	-15	-15	-21	-27
Net Income / (Loss) Continuing Operations	22	-10	-7.09	-11	-15	-11	-14	-18	-25	-28
Consolidated Net Income / (Loss)	22	-10	-7.09	-11	-15	-11	-14	-18	-25	-28
Depreciation Expense	-0.97	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.03	0.03
Amortization Expense	-	-0.36	-0.29	-0.14	-0.26	-0.44	-0.43	-0.33	-2.25	-2.69
Non-Cash Adjustments To Reconcile Net Income	-6.09	2.51	0.91	0.61	1.08	1.06	1.78	2.71	3.08	5.37
Changes in Operating Assets and Liabilities, net	1.93	-0.89	-3.83	5.93	3.94	-1.93	-2.56	0.68	3.06	-1.72
Net Cash From Investing Activities	-6.88	-13	18	22	-12	-8.24	-5.51	1.17	-259	-23
Net Cash From Continuing Investing Activities	-6.88	-13	18	22	-12	-8.24	-5.51	1.17	-259	-23
Purchase of Property, Plant & Equipment	0.05	-0.03	-0.01	-0.02	-0.07	-0.01	-0.03	-0.02	-0.03	-0.03
Purchase of Investments	-6.93	-15	-3.86	-	-27	-26	-20	-6.81	-278	-108
Sale and/or Maturity of Investments	-	2.00	22	22	16	18	15	8.00	19	85
Net Cash From Financing Activities	97	-	0.00	-	138	-4.87	218	-2.20	0.30	40
Net Cash From Continuing Financing Activities	97	-	0.00	-	138	-4.87	218	-2.20	0.30	40
Other Financing Activities, net	-	-	0.00	-	138	-4.87	230	0.05	0.30	0.48

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	83	179	374
Total Current Assets	82	177	281
Cash & Equivalents	15	132	23
Short-Term Investments	60	41	252
Accounts Receivable	4.70	0.29	0.81
Prepaid Expenses	0.91	3.26	4.86
Other Current Assets	0.94	0.18	0.00
Plant, Property, & Equipment, net	0.14	0.19	0.19
Total Noncurrent Assets	0.94	1.77	93
Long-Term Investments	-	0.00	82
Other Noncurrent Operating Assets	0.94	1.77	11
Total Liabilities & Shareholders' Equity	83	179	374
Total Liabilities	9.45	11	22
Total Current Liabilities	8.23	9.63	18
Accounts Payable	1.17	2.61	4.58
Accrued Expenses	6.61	6.50	13
Current Deferred Revenue	0.10	0.10	0.48
Other Current Liabilities	0.35	0.42	0.32
Total Noncurrent Liabilities	1.23	0.90	3.08
Noncurrent Deferred Revenue	0.79	0.74	1.91
Other Noncurrent Operating Liabilities	0.44	0.17	1.17
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	118	0.00	0.00
Total Equity & Noncontrolling Interests	-44	169	352
Total Preferred & Common Equity	-44	169	352
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-44	169	352
Common Stock	1.66	258	527
Retained Earnings	-46	-89	-174
Accumulated Other Comprehensive Income / (Loss)	-0.16	0.05	0.11

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	83	79	192	382	369	354
Total Current Assets	83	79	191	381	366	287
Cash & Equivalents	49	63	157	330	314	34
Short-Term Investments	30	15	33	47	47	247
Accounts Receivable	-	-	0.75	0.44	0.84	1.39
Prepaid Expenses	2.91	1.05	0.83	3.01	3.31	3.68
Other Current Assets	-	-	-	0.44	0.84	1.29
Plant, Property, & Equipment, net	0.00	0.00	0.20	0.20	0.19	0.19
Total Noncurrent Assets	0.00	0.00	0.81	1.34	3.08	67
Long-Term Investments	-	-	-	-	-	61
Other Noncurrent Operating Assets	0.00	0.00	0.81	1.34	3.08	5.09
Total Liabilities & Shareholders' Equity	83	79	192	382	369	354
Total Liabilities	5.98	4.03	14	9.78	11	16
Total Current Liabilities	5.98	4.03	13	8.96	10	16
Accounts Payable	1.08	0.81	1.37	2.61	3.70	7.57
Accrued Expenses	4.90	3.22	11	5.85	5.86	7.73
Current Deferred Revenue	-	-	0.10	0.10	0.10	0.10
Other Current Liabilities	0.00	0.00	0.41	0.40	0.38	0.31
Total Noncurrent Liabilities	0.00	0.00	1.00	0.82	0.71	0.64
Noncurrent Deferred Revenue	-	-	0.75	0.72	0.68	0.64
Other Noncurrent Operating Liabilities	0.00	0.00	0.26	0.10	0.03	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	77	75	178	373	358	338
Total Preferred & Common Equity	77	75	178	373	358	338
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	77	75	178	373	358	338
Common Stock	509	509	257	476	479	483
Retained Earnings	-431	-434	-79	-103	-121	-146
Accumulated Other Comprehensive Income / (Loss)	-0.02	-0.00	-0.00	-0.03	-0.04	0.68

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	-55.96%	120.63%
EBITDA Growth	58.61%	-64.19%	-118.56%
EBIT Growth	60.34%	-63.12%	-111.79%
NOPAT Growth	60.23%	-62.17%	-111.45%
Net Income Growth	59.97%	-52.95%	-95.08%
EPS Growth	-2,424.81%	74.06%	69.82%
Operating Cash Flow Growth	51.17%	-26.80%	-112.09%
Free Cash Flow Firm Growth	56.17%	-32.28%	-133.36%
Invested Capital Growth	56.89%	-164.34%	7.34%
Revenue Q/Q Growth	0.00%	-62.88%	16.19%
EBITDA Q/Q Growth	0.00%	-213.59%	-25.10%
EBIT Q/Q Growth	0.00%	-227.54%	-23.43%
NOPAT Q/Q Growth	0.00%	-226.56%	-22.87%
Net Income Q/Q Growth	0.00%	-223.52%	-26.65%
EPS Q/Q Growth	0.00%	82.25%	-117.75%
Operating Cash Flow Q/Q Growth	0.00%	-8.87%	-24.91%
Free Cash Flow Firm Q/Q Growth	-692.81%	-2,741.30%	-10.56%
Invested Capital Q/Q Growth	0.00%	57.80%	4.57%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-468.75%	-1,747.59%	-1,731.19%
Operating Margin	-462.91%	-1,704.67%	-1,633.75%
EBIT Margin	-461.60%	-1,709.80%	-1,641.28%
Profit (Net Income) Margin	-443.76%	-1,541.22%	-1,362.77%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	96.13%	90.14%	83.03%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-23.12%	-35.92%	-32.60%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-21.70%	-36.81%	-36.98%
Return on Assets (ROA)	-20.86%	-33.18%	-30.71%
Return on Common Equity (ROCE)	-12.04%	-18.44%	-32.60%
Return on Equity Simple (ROE_SIMPLE)	64.18%	-25.79%	-24.11%
Net Operating Profit after Tax (NOPAT)	-21	-34	-71
NOPAT Margin	-324.04%	-1,193.27%	-1,143.62%
Net Nonoperating Expense Percent (NNEP)	-6.09%	-7.89%	-5.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-19.97%	-20.23%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	105.08%	642.57%	400.87%
R&D to Revenue	457.83%	1,162.10%	1,332.88%
Operating Expenses to Revenue	562.91%	1,804.67%	1,733.75%
Earnings before Interest and Taxes (EBIT)	-30	-48	-102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-49	-108
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.91	1.83
Price to Tangible Book Value (P/TBV)	0.00	0.91	1.83
Price to Revenue (P/Rev)	3.63	54.53	103.48
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	10.25	0.00	46.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.02
Leverage Ratio	1.11	1.08	1.06
Compound Leverage Factor	1.07	0.98	0.88
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	160.24%	0.00%	0.00%
Common Equity to Total Capital	-60.24%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.67	8.33	17.28
Noncontrolling Interest Sharing Ratio	47.91%	48.66%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.97	18.43	15.22
Quick Ratio	9.75	18.07	14.96
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-23	-31	-72
Operating Cash Flow to CapEx	-20,913.67%	-33,510.00%	-74,457.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.02	0.02
Accounts Receivable Turnover	0.00	1.13	11.33
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.69	17.28	32.90
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	322.51	32.23
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	322.51	32.23
Capital & Investment Metrics	-	-	-
Invested Capital	-1.83	-4.85	-4.49
Invested Capital Turnover	-2.11	-0.85	-1.34
Increase / (Decrease) in Invested Capital	2.42	-3.01	0.36
Enterprise Value (EV)	66	-20	288
Market Capitalization	23	154	645
Book Value per Share	($50.75)	$11.40	$11.91
Tangible Book Value per Share	($50.75)	$11.40	$11.91
Total Capital	74	169	352
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-75	-174	-357
Capital Expenditures (CapEx)	0.14	0.11	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.68	-5.90	-13
Debt-free Net Working Capital (DFNWC)	74	168	262
Net Working Capital (NWC)	74	168	262
Net Nonoperating Expense (NNE)	7.68	9.83	14
Net Nonoperating Obligations (NNO)	-75	-174	-357
Total Depreciation and Amortization (D&A)	-0.46	-1.07	-5.61
Debt-free, Cash-free Net Working Capital to Revenue	-26.21%	-208.70%	-205.12%
Debt-free Net Working Capital to Revenue	1,150.19%	5,938.43%	4,209.33%
Net Working Capital to Revenue	1,150.19%	5,938.43%	4,209.33%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.29)	($8.45)	($2.55)
Adjusted Weighted Average Basic Shares Outstanding	59.37M	5.15M	33.31M
Adjusted Diluted Earnings per Share	($1.29)	($8.45)	($2.55)
Adjusted Weighted Average Diluted Shares Outstanding	59.37M	5.15M	33.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	60.64M	29.35M	32.13M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-34	-71
Normalized NOPAT Margin	-324.04%	-1,193.27%	-1,143.62%
Pre Tax Income Margin	-443.76%	-1,541.22%	-1,362.77%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	-21.23%	-91.29%	83.61%	92.26%	135.06%	190.15%
EBITDA Growth	47.67%	0.00%	65.82%	32.12%	-74.86%	-166.78%	-130.57%	-89.32%	-98.62%	-161.25%
EBIT Growth	55.06%	0.00%	67.71%	34.60%	-92.56%	-163.55%	-133.53%	-88.68%	-87.58%	-149.33%
NOPAT Growth	54.76%	0.00%	67.76%	34.88%	-90.93%	-144.31%	-132.25%	-88.55%	-89.73%	-146.34%
Net Income Growth	0.00%	0.00%	69.11%	35.50%	-89.66%	-154.09%	-93.93%	-58.05%	-70.52%	-169.24%
EPS Growth	0.00%	0.00%	-1,976.92%	-4,289.66%	57.53%	170.29%	93.33%	95.99%	80.42%	-104.70%
Operating Cash Flow Growth	216.41%	0.00%	47.91%	71.93%	-161.02%	-33.93%	-45.28%	-207.08%	-112.84%	-131.52%
Free Cash Flow Firm Growth	33.08%	2,773.48%	46.70%	34.89%	105.26%	-133.55%	-45.09%	-78.23%	-6,154.62%	-274.84%
Invested Capital Growth	100.00%	56.89%	43.35%	20.23%	0.00%	-164.34%	-41.75%	16.73%	59.03%	7.34%
Revenue Q/Q Growth	0.00%	347.06%	-90.92%	103.57%	-4.64%	-50.54%	91.25%	113.16%	16.59%	-38.95%
EBITDA Q/Q Growth	47.92%	319.36%	-139.64%	-49.91%	-34.16%	16.23%	-36.86%	-23.09%	-40.74%	-10.19%
EBIT Q/Q Growth	54.65%	349.59%	-137.60%	-53.70%	-33.51%	17.63%	-38.16%	-24.18%	-32.73%	-9.49%
NOPAT Q/Q Growth	54.35%	454.22%	-126.28%	-53.27%	-33.82%	17.79%	-37.73%	-24.43%	-34.66%	-6.74%
Net Income Q/Q Growth	54.93%	350.89%	-136.30%	-57.14%	-32.52%	28.45%	-30.15%	-28.07%	-42.98%	-12.97%
EPS Q/Q Growth	-2,968.97%	-158.31%	64.77%	-57.16%	70.31%	527.51%	-103.34%	5.56%	-45.10%	-2.70%
Operating Cash Flow Q/Q Growth	197.16%	-154.05%	-16.19%	54.00%	-111.20%	-18.63%	-26.04%	2.76%	-46.39%	-29.05%
Free Cash Flow Firm Q/Q Growth	37.02%	307.29%	-142.81%	-16.50%	105.08%	-1,422.96%	-85.13%	-43.11%	-72.74%	18.10%
Invested Capital Q/Q Growth	100.00%	0.00%	-67.28%	2.58%	-284.38%	57.80%	10.29%	42.77%	-89.11%	4.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-781.67%	383.54%	-1,674.79%	-1,233.33%	-1,735.17%	-2,938.95%	-2,103.09%	-1,214.49%	-1,466.11%	-2,646.23%
Operating Margin	-703.67%	390.27%	-1,614.08%	-1,215.27%	-1,705.52%	-2,835.01%	-2,041.65%	-1,191.84%	-1,376.61%	-2,406.94%
EBIT Margin	-699.06%	390.27%	-1,616.60%	-1,220.54%	-1,708.87%	-2,846.17%	-2,056.06%	-1,197.80%	-1,363.67%	-2,445.70%
Profit (Net Income) Margin	-663.60%	372.41%	-1,489.29%	-1,149.64%	-1,597.73%	-2,311.38%	-1,573.00%	-945.09%	-1,159.02%	-2,144.80%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	94.93%	95.42%	92.12%	94.19%	93.50%	81.21%	76.51%	78.90%	84.99%	87.70%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-23.12%	-11.03%	-6.17%	-15.09%	-35.92%	-22.31%	-26.19%	-25.99%	-32.60%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	18.34%	-80.22%	-75.63%	-135.19%	-61.28%	-28.46%	-22.04%	-26.77%	-55.11%
Return on Assets (ROA)	0.00%	17.50%	-73.90%	-71.24%	-126.40%	-49.76%	-21.77%	-17.39%	-22.75%	-48.33%
Return on Common Equity (ROCE)	0.00%	-12.04%	-11.03%	-6.17%	-15.09%	-18.44%	-22.31%	-26.19%	-25.99%	-32.60%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-16.29%	-8.69%	-7.55%	0.00%	-13.47%	-15.82%	-19.86%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.78	20	-5.38	-8.24	-11	-9.07	-12	-16	-21	-22
NOPAT Margin	-492.57%	390.27%	-1,129.85%	-850.69%	-1,193.86%	-1,984.51%	-1,429.15%	-834.29%	-963.63%	-1,684.86%
Net Nonoperating Expense Percent (NNEP)	-2.08%	-0.74%	-1.44%	-2.67%	-3.93%	-1.20%	-0.55%	-0.94%	-1.59%	-2.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-5.37%	-	-	-	-6.34%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	188.32%	-176.07%	485.71%	257.17%	944.05%	1,013.57%	645.31%	321.90%	300.55%	515.01%
R&D to Revenue	615.35%	-114.21%	1,228.36%	1,058.10%	861.47%	1,921.44%	1,496.34%	969.94%	1,176.06%	1,991.93%
Operating Expenses to Revenue	803.67%	-290.27%	1,714.08%	1,315.27%	1,805.52%	2,935.01%	2,141.65%	1,291.84%	1,476.61%	2,506.94%
Earnings before Interest and Taxes (EBIT)	-8.20	20	-7.70	-12	-16	-13	-18	-22	-30	-32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.17	20	-7.97	-12	-16	-13	-18	-23	-32	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.62	0.62	4.65	0.91	2.36	2.12	2.38	1.83
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.62	0.62	4.65	0.91	2.36	2.12	2.38	1.83
Price to Revenue (P/Rev)	0.00	3.63	6.99	5.85	108.93	54.53	273.08	184.45	149.78	103.48
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	10.25	0.00	0.00	83.99	0.00	156.13	96.86	85.93	46.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	549.99	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.02	-1.04	-1.03	-1.06	-1.03	-1.02	-1.01	-1.03	-1.02
Leverage Ratio	1.09	1.11	1.22	1.21	1.08	1.08	1.04	1.03	1.06	1.06
Compound Leverage Factor	1.03	1.06	1.12	1.14	1.01	0.88	0.79	0.82	0.90	0.93
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	160.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-60.24%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	2.66	-1.51	-0.16	35.64	8.98	54.68	42.94	29.58	17.90
Noncontrolling Interest Sharing Ratio	0.00%	47.91%	0.00%	0.00%	0.00%	48.66%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	9.97	13.95	19.49	14.64	18.43	42.52	36.46	18.30	15.22
Quick Ratio	0.00	9.75	13.07	19.23	14.57	18.07	42.13	36.05	17.98	14.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.71	18	-7.73	-9.00	0.46	-6.06	-11	-16	-28	-23
Operating Cash Flow to CapEx	0.00%	-30,520.69%	-73,457.14%	-22,528.57%	-15,372.31%	-118,540.00%	-46,690.63%	-85,458.82%	-85,068.00%	-88,529.03%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.05	0.05	0.06	0.08	0.02	0.01	0.02	0.02	0.02
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00	5.01	11.33
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	1.69	0.00	0.00	0.00	17.28	0.00	0.00	27.95	32.90
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	322.51	0.00	0.00	72.82	32.23
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	322.51	0.00	0.00	72.82	32.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-1.83	-3.07	-2.99	-11	-4.85	-4.35	-2.49	-4.71	-4.49
Invested Capital Turnover	0.00	-2.11	-1.62	-2.33	-1.33	-0.85	-0.87	-1.50	-0.66	-1.34
Increase / (Decrease) in Invested Capital	2.93	2.42	2.35	0.76	-11	-3.01	-1.28	0.50	6.78	0.36
Enterprise Value (EV)	83	66	-32	-32	639	-20	503	399	461	288
Market Capitalization	83	23	48	46	829	154	880	760	804	645
Book Value per Share	$0.00	($50.75)	$1.28	$1.23	$2.94	$11.40	$12.70	$12.21	$11.51	$11.91
Tangible Book Value per Share	$0.00	($50.75)	$1.28	$1.23	$2.94	$11.40	$12.70	$12.21	$11.51	$11.91
Total Capital	0.00	74	77	75	178	169	373	358	338	352
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-75	-80	-78	-190	-174	-377	-361	-343	-357
Capital Expenditures (CapEx)	-0.05	0.03	0.01	0.02	0.07	0.01	0.03	0.02	0.03	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-1.68	-2.53	-2.99	-11	-5.90	-5.07	-5.05	-9.34	-13
Debt-free Net Working Capital (DFNWC)	0.00	74	77	75	178	168	372	356	272	262
Net Working Capital (NWC)	0.00	74	77	75	178	168	372	356	272	262
Net Nonoperating Expense (NNE)	2.01	0.94	1.71	2.90	3.73	1.49	1.26	2.06	4.24	6.10
Net Nonoperating Obligations (NNO)	0.00	-75	-81	-78	-190	-174	-377	-361	-343	-357
Total Depreciation and Amortization (D&A)	-0.97	-0.35	-0.28	-0.12	-0.24	-0.42	-0.41	-0.31	-2.23	-2.66
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-26.21%	-36.66%	-38.02%	-151.00%	-208.70%	-157.23%	-122.61%	-174.13%	-205.12%
Debt-free Net Working Capital to Revenue	0.00%	1,150.19%	1,123.73%	948.92%	2,343.02%	5,938.43%	11,537.44%	8,636.67%	5,064.83%	4,209.33%
Net Working Capital to Revenue	0.00%	1,150.19%	1,123.73%	948.92%	2,343.02%	5,938.43%	11,537.44%	8,636.67%	5,064.83%	4,209.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($22.99)	($0.48)	($0.05)	($3.78)	$16.16	($0.54)	($0.51)	($0.74)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	0.00	874.23K	60.65M	60.65M	3.91M	5.15M	25.67M	34.23M	34.24M	33.31M
Adjusted Diluted Earnings per Share	$0.00	($22.99)	($0.48)	($0.05)	($3.78)	$16.16	($0.54)	($0.51)	($0.74)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	874.23K	60.65M	60.65M	3.91M	5.15M	25.67M	34.23M	34.24M	33.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	60.64M	60.65M	60.66M	14.82M	29.35M	29.35M	29.35M	29.60M	32.13M
Normalized Net Operating Profit after Tax (NOPAT)	-5.78	14	-5.38	-8.24	-11	-9.07	-12	-16	-21	-22
Normalized NOPAT Margin	-492.57%	273.19%	-1,129.85%	-850.69%	-1,193.86%	-1,984.51%	-1,429.15%	-834.29%	-963.63%	-1,684.86%
Pre Tax Income Margin	-663.60%	372.41%	-1,489.29%	-1,149.64%	-1,597.73%	-2,311.38%	-1,573.00%	-945.09%	-1,159.02%	-2,144.80%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Dianthus Therapeutics' Financials

When does Dianthus Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Dianthus Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Dianthus Therapeutics' net income changed over the last 2 years?

Dianthus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$84.97 million in 2024, rising from -$28.48 million in 2022. The previous period was -$43.56 million in 2023.

What is Dianthus Therapeutics's operating income?

Dianthus Therapeutics's total operating income in 2024 was -$101.86 million, based on the following breakdown:

Total Gross Profit: $6.24 million
Total Operating Expenses: $108.10 million

How has Dianthus Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Dianthus Therapeutics' total revenue changed from $6.42 million in 2022 to $6.24 million in 2024, a change of -2.8%.

How much debt does Dianthus Therapeutics have?

Dianthus Therapeutics' total liabilities were at $21.53 million at the end of 2024, a 104.4% increase from 2023, and a 127.7% increase since 2022.

How much cash does Dianthus Therapeutics have?

In the past 2 years, Dianthus Therapeutics' cash and equivalents has ranged from $15.37 million in 2022 to $132.33 million in 2023, and is currently $22.79 million as of their latest financial filing in 2024.

How has Dianthus Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Dianthus Therapeutics' book value per share changed from -50.75 in 2022 to 11.91 in 2024, a change of -123.5%.

Remove Ads

Related Companies

This page (NASDAQ:DNTH) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Financials

Frequently Asked Questions About Dianthus Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Financials

Annual Income Statements for Dianthus Therapeutics

Quarterly Income Statements for Dianthus Therapeutics

Annual Cash Flow Statements for Dianthus Therapeutics

Quarterly Cash Flow Statements for Dianthus Therapeutics

Annual Balance Sheets for Dianthus Therapeutics

Quarterly Balance Sheets for Dianthus Therapeutics

Annual Metrics and Ratios for Dianthus Therapeutics

Quarterly Metrics and Ratios for Dianthus Therapeutics

Frequently Asked Questions About Dianthus Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools